Should I Buy CRBP? CRBP 2026 Analysis

Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

7.830

1 Day change

5.95%

52 Week Range

20.560

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: trend is technically bearish and short-term pattern stats skew negative (next day/week).
Options positioning is bullish (very low put/call ratios), but it’s not being confirmed by price trend or proprietary signals.
Analyst upside targets are very high, but heavy insider selling is a clear near-term red flag.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Technical Analysis

Current price ~7.95 (regular market -1.54%); pre-market +2.77% bounce looks like a counter-trend pop.
Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downtrend across short/medium/long horizons.
MACD histogram (-0.00379) is below zero and negatively expanding → downside momentum is still building.
RSI(6) ~29.34 (near oversold): could allow a brief bounce, but oversold conditions alone are not a durable buy signal in a downtrend.
Key levels: immediate resistance at Pivot 8.703 (then R1 9.341); supports at S1 8.065 and S2 7.671. Price is below Pivot and flirting with lower support zones.
Quant/pattern outlook: ~80% chance of -2.86% next day and -5.61% next week (only slightly positive over next month).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment skew is bullish: Put/Call OI 0.35 and Put/Call volume 0.14 suggest traders are leaning calls over puts.
Activity is elevated: today’s option volume 113 vs 30-day average (32.1x), and today’s open interest vs average is ~104% → attention has picked up.
Volatility is extremely high (HV ~123%, 30D IV ~101%): market is pricing big swings; direction is less certain despite bullish call skew.
IV context: IV percentile ~42.8 and IV rank ~16.6 (not at extreme highs vs its own history), even though absolute IV is huge.

Technical Summary

Sell

Buy

Positive Catalysts

- Street narrative remains constructive on pipeline optionality: obesity/CRB-913 early signals + oncology program perceived as de-risked by some analysts.
- Analyst targets imply very large upside if programs execute (recent targets cited: $32 and $53).
- Call-heavy options positioning and unusually high options activity can precede momentum bursts if price breaks back above ~8.70–9.34 resistance band.

Neutral/Negative Catalysts

- Trend is bearish with weakening momentum (MACD expanding negative; bearish MA stack), which typically punishes impatient dip-buys.
- Insider activity: insiders are selling, with selling amount up ~2235.89% over the last month (strong negative signal near-term).
- No supportive near-term news flow in the past week to act as a catalyst.
- Pattern-based short-term probabilities favor further downside over the next day/week.
- Hedge funds are neutral (no supportive “smart money” accumulation signal in the last quarter).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (0% YoY) — effectively pre-commercial with no revenue contribution.
Net loss improved to -$23.342M (improved ~69.35% YoY), indicating reduced burn vs prior year period.
EPS improved to -1.90 (improved ~65.22% YoY), but profitability is still far away and performance is primarily driven by expense management rather than growth.
Overall: improving losses, but not a growth story in reported revenue yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst tone is bullish overall.
RBC Capital (2025-12-11): Outperform, PT $53; highlights early efficacy hints for CRB-913 and undervaluation.
RBC Capital (2025-11-13): Outperform, PT trimmed slightly to $53 from $55; says oncology opportunity better de-risked.
Stifel (2025-12-04): Buy, PT raised to $32 from $28; cites pipeline/optionality improvements.
Wall Street pros: large upside optionality (oncology + obesity), “under-the-radar” valuation argument.
Wall Street cons: still highly speculative, dependent on clinical execution/timing; insider selling conflicts with the bullish research narrative in the near term.

8 Analyst Rating

Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 46.71 USD with a low forecast of 38 USD and a high forecast of 53 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.390

Low

Averages

46.71

High

Current: 7.390

Low

Averages

46.71

High

RBC Capital

Outperform

maintain

$53

AI Analysis

2025-12-11

Reason

RBC Capital

Price Target

$53

AI Analysis

2025-12-11

maintain

Outperform

Reason

RBC Capital notes that Corbus Pharmaceuticals has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse agonist, and management also hosted a conference call to discuss the data in detail. Early hints at efficacy and possibility Corbus could navigate a therapeutic window better than prior CB1 efforts should draw attention to this under-the-radar asset, with more robust de-risking data potentially only a few quarters away. At a $35M EV, with a cancer drug in '701 RBC views as low-risk, and a higher-risk but potentially very large-opportunity obesity asset, the firm believes the company is undervalued. The firm has an Outperform rating on the shares with a price target of $53.

Stifel

Stephen Willey

Buy

maintain

$28 -> $32

2025-12-04

Reason

Stifel

Stephen Willey

Price Target

$28 -> $32

2025-12-04

maintain

Buy

Reason

Stifel analyst Stephen Willey raised the firm's price target on Crescent Biopharma to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun deal creates "greater pipeline and CR-001 development and optionality," with Crescent "securing ex-Greater China rights to an ADC with a clinically-validated target antigen and linker/payload and positioning itself to leverage data generated from Kelun's interrogation of CR-001-based combinations with its other ADCs."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRBP

Unlock Now

CRBP Should I Buy

CRBP Should I Buy

Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch